Fig. 2

Enhancer of zeste homolog 2 (EZH2) is a target gene of miR-138 in cervical cancer cells. a Sequence alignment between miR-138 and the predicted binding site in the wild-type (WT) 3′-untranslated region (UTR) of EZH2. The sequence of the EZH2 3′-UTR carrying a mutation in the miR-138 binding site (Mut) was also employed for luciferase reporter analysis. b Relative luciferase activity in SiHa and C33A cells transfected with the WT or Mut EZH2 3′-UTR-Luc with or without miR‐138 overexpression. c Quantitative RT-PCR analysis was applied to determine the relative mRNA levels of EZH2 in SiHa and C33A cells transfected with the miR-138 mimic, miR-138 inhibitor, or negative-control miRNA (miR-NC). d Western blot analysis was applied to determine the protein levels of EZH2, E-cadherin, and N-cadherin in SiHa and C33A cells transfected with the miR-138 mimic, miR-138 inhibitor, or miR-NC. β-actin served as a loading control